Search results
Results from the WOW.Com Content Network
Insulin resistance, or low insulin sensitivity, happens when cells throughout the body don’t respond properly to the hormone insulin, especially cells in muscles, fat and the liver. Insulin is a ...
The hyperglycemic clamps are often used to assess insulin secretion capacity. Hyperinsulinemic-euglycemic clamp technique: The plasma insulin concentration is acutely raised and maintained at 100 μU/ml by a continuous infusion of insulin. Meanwhile, the plasma glucose concentration is held constant at basal levels by a variable glucose infusion.
IR is insulin resistance and %β is the β-cell function (more precisely, an index for glucose tolerance, i.e. a measure for the ability to counteract the glucose load). Insulin is given in μU/mL. [7] Glucose and insulin are both during fasting. [2] This model correlated well with estimates using the euglycemic clamp method (r = 0.88). [2]
Insulin resistance can be improved or reversed with lifestyle approaches, such as weight reduction, exercise, and dietary changes. There are multiple ways to measure insulin resistance such as fasting insulin levels or glucose tolerance tests, but these are not often used in clinical practice.
The insulin syringe was the first syringe that is considered low dead space. It was initially created with low dead space for accurate measuring and mixing of fast and slow acting insulin, which had the added benefit of wasting as little of the expensive drug as possible.
The dilution of insulin is such that 1 mL of insulin fluid has 100 standard "units" of insulin. [6] A typical insulin vial may contain 10 mL, for 1000 units. Insulin syringes are made specifically for a patient to inject themselves, and have features to assist this purpose when compared to a syringe for use by a healthcare professional:
Historically, pen needles were manufactured in lengths up to 12.7mm. Over time, pen needles designed for insulin pens have become shorter, and a 4mm long needle is considered sufficient for most people to administer subcutaneously correctly. [23] In 1989, an injector pen form of human growth hormone was licensed in New Zealand. [28]
Reaven's work on insulin resistance and diabetes mellitus with John W. Farquhar goes back at least to 1965. [3] A long-term researcher into diabetes, he achieved significant notability with his 1988 Banting Lecture (organized annually by the American Diabetes Association in memory of Frederick Banting).